Entourage effect
 | This article provides insufficient context for those unfamiliar with the subject. (October 2014) |
Entourage effect is a phrase that was introduced in cannabinoid science in 1998 by S. Ben-Shabat, with Raphael Mechoulam, to represent a novel endogenous cannabinoid molecular regulation route. Biological activity assayed together with inactive compounds. References whole plant and whole person caregiver synergy treatments over isolated compound pharmacological dosages.[1][2][3][4][5][6][7][8]
External links
References
- ^ Lee, Martin A. (Sep 13, 2013). Smoke Signals: A Social History of Marijuana-Medical, Recreational and Scientific. Scribner. p. 465. ISBN 978-1439102619.
- ^ Ben-Shabat, Shimon (July 17, 1998). "An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity". European Journal of Pharmacology. 353 (1): 23–31. doi:10.1016/S0014-2999(98)00392-6.
- ^ Andersson, Karl-Erik (Feb 4, 2011). Urinary Tract. eBook: Springer Science & Business Media. p. 438.
- ^ Newnes (March 5, 2010). Comprehensive Natural Products II: Chemistry and Biology:. eBook: Google. p. 220.
- ^ Guy, Geoffrey William (July 1, 2004). The Medicinal Uses of Cannabis and Cannabinoids (1st ed.). Pharmaceutical Press. p. 114. ISBN 978-0853695172.
- ^ Castle, David (May 27, 2004). Marijuana and Madness: Psychiatry and Neurobiology. eBook: Google. p. 8.
- ^ Russo, Ethan B (Aug 2011). "Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects". Br J Pharmacol. 163 (7): 1344–1364. doi:10.1111/j.1476-5381.2011.01238.x. PMC 3165946. PMID 21749363.
- ^ Gardner, Fred (2011). "Terpenoids, 'minor' cannabinoids contribute to 'entourage effect' of Cannabis-based medicines". The Journal of Cannavis in Clinical Practice: 1.
 | This Cannabis-related article is a stub. You can help Wikipedia by expanding it. |